Print Services: Subscribe | Home Delivery Web: Mobile Edition |

 
Site Web Search powered by YAHOO!SEARCH
 
Silicon Valley 150
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Gilead Sciences, Inc. (NQ: GILD)
51.69 USD  -0.25 (-0.48%)
Streaming Delayed Price  /  Updated: 9:38 AM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about Gilead Sciences, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Secrets to Making Money in PG, MRK, GILD and F
June 18, 2013
from Marketwired News Releases
Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics
June 18, 2013
Editor Note: For more information about this release, please scroll to bottom. Read More
from PR Newswire
Markets Soar Ahead Of Fed Meeting
June 17, 2013
The markets closed sharply higher with the Dow soaring 109 points to 15,179 as investors awaited word from the Federal Reserve about possible changes to its bond buying program. Nasdaq climbed 28... Read More
category Market News
from MarketMinute.com Market Updates
CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors
June 17, 2013
from Business Wire News Releases
Gilead Sciences to Present at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18
June 17, 2013
from Business Wire News Releases
Oppenheimer Reiterates Outperform Rating on Gilead Sciences Following Initial Idelalisib Ph.II Results
June 17, 2013
In a report published Monday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating and $61.00 price target on Gilead Sciences (NASDAQ: GILD ). In the report, Oppenheimer noted, “GILD... Read More
category Reiteration , Oppenheimer , Benzinga , and 4 more.
from Latest Articles from Benzinga.com
Gilead anuncia los datos provisionales de Fase 2 de idelalisib, que muestran una respuesta en el linfoma no-Hodgkin indolente refractario
June 17, 2013
from Business Wire Spanish
Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin’s Lymphoma
June 17, 2013
from Business Wire News Releases
Weekly Wrap-Up + Market Forecast + Sector Watch: SPX, Nasdaq, GLD, BTK, XLE, XLF, GS, MA, V, JPM, BAC, APA, APC, HES, OXY, CELG, ONXX, GILD, BIIB, REGN, ALXN
June 17, 2013
Last weekend, in my Market Forecast, I wrote: "For the new week, stocks may need a little pause and consolidation to start the week.  There is resistance between 1650 and 1660.  On the down side, we... Read More
category XLE , REGN , APA , and 17 more.
from Wang's Happy Trading
Gilead Sciences (GILD) Breaks Through Resistance at $52.47
June 14, 2013
from Comtex SmarTrend® News Briefs
Trace Insider Trading for Micron, QUALCOMM, Gilead Sciences, Wells Fargo, EMC, and Home Depot
June 14, 2013
from PR Newswire
Read It-Then Watch; on the Up and Up; SCOTUS Rules
June 13, 2013
Gannett acquires Belo; retail/auto sales up; Supreme Court has ruled unanimously for no patent on human genes. Read More
category executiveedge , Belo Corp
from CNBC.com News
Growing Uses For $4B-a-Year Gilead HIV Drugs
June 13, 2013
category GILD
from YCharts
Notable Analyst Rating Changes 06/13: (BBRY) (ROST) (GILD) Upgraded; (MPW) (SWY) (PPO) Downgraded
June 13, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8414366 for the full story. Read More
from StreetInsider.com News Articles
Upgrade Alert for Gilead Sciences (GILD)
June 13, 2013
from Comtex SmarTrend® News Briefs
Stock Upgrades: Bulls Run on Adidas AG
June 13, 2013
Wall Street ratings agencies set the tone for today's stock market. Read More
category CELG , GILD
from Minyanville Headlines
Top Stocks Upgrades/Downgrades June 13, 2013
June 13, 2013
UPGRADES Celgene (NASDAQ:CELG) upgraded to Buy from Hold at Argus – Target $140 Gilead (NASDAQ:GILD) upgraded to Buy from Hold at Argus – Target $62 Ross Stores (NASDAQ:ROST) upgraded to Buy from... Read More
category Latest , Market Today
from Wall Street Pit
The Straight Truth, Investing in FITB, HTZ, BRCM and GILD
June 13, 2013
from Marketwired News Releases
Argus Upgrades Gilead Sciences (GILD) to Buy
June 13, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8413242 for the full story. Read More
from StreetInsider.com News Articles
Gilead's (GILD) Viread Reduces HIV Risk by 49% for Drug Users - Bloomberg
June 12, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8409864 for the full story. Read More
from StreetInsider.com News Articles
Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)
June 12, 2013
Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB ), saw the most significant rise in short interest between the May 15 and May 31 settlement dates. The number of shares... Read More
category Regeneron Pharmaceuticals , amgen , Benzinga , and 35 more.
from Latest Articles from Benzinga.com
Some Healthcare Hot Stock Update (MRK, BSX, GILD, BMY)
June 11, 2013
New York, NY -- (SBWIRE) -- 06/11/2013 -- Merck & Co. Inc. (NYSE: MRK) missing a U.S. is attractive judge's bid to get back a patent-infringement declare against generic-drug manufacturer Apotex Inc.... Read More
from SBWire - Latest Press Releases
Profitable Trading Secrets Revealed in SFD, GILD, CMCSA and ARR
June 11, 2013
from Marketwired News Releases
UPDATE 1-Former Bristol-Myers executive admits to insider trading
June 10, 2013
* Defendant accused of buying options in takeover targets Read More
category companyNews
from Reuters: Company News
Former Bristol-Myers executive admits to insider trading
June 10, 2013
A former Bristol-Myers Squibb Co finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology company that the drugmaker was preparing... Read More
from FOX News
Former Bristol-Myers executive admits to insider trading
June 10, 2013
* Defendant accused of buying options in takeover targets Read More
category companyNews
from Reuters: Company News
Gilead Sciences to Present at the Goldman Sachs 34th Annual Healthcare Conference on Tuesday, June 11
June 10, 2013
from Business Wire News Releases
Notable 50-Day SMA Crossers 06/10: (P) (APRI) (MON) Above; (OCLR) (MCD) (GILD) Below
June 10, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8403423 for the full story. Read More
from StreetInsider.com News Articles
Gilead Sciences (GILD) slipped on operating margin
June 10, 2013
Gilead Sciences (NASDAQ: GILD) moved down 0.3% to $52.75. Gilead Sciences' trailing-12-month operating margin is 40.83%. Share volume was 1.7 million, compared to an all-day average of 12.4 million Read More
from BAYSTREET RSS FEED
Gilead anuncia la designación de la Agencia de Alimentos y Fármacos (FDA) de EE.UU. de análisis prioritario para sofosbuvir para el tratamiento de la hepatitis C
June 10, 2013
from Business Wire Spanish
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Copyright 2008 San Jose Mercury News
Help | Site Map | Advertise | Newsletters | Home Delivery | Copyright | About MediaNews Group | RSS | Ethics Policy

Privacy Policy  |   Site Map